Dr. Nassim Nabbout has been recognized as an author in a trial of patients with diagnosed squamous cell carcinoma of the anal canal (SCCAC) and how adding cetuximab to chemoradiotherapy treatments may affect results. This trial was published in the Journal of Clinical Oncology, one of the most respected publications in the field (the article is available in its entirety below). A total of 63 patients were accrued between January of 2007 and May 2012. The trial has concluded and thus brought about new information on SCCAC, a rare yet potentially curable disease. The Cancer Center of Kansas is so proud to have physicians dedicated to the continuation of research in the field of oncology. CCK is one of only 46 cancer research programs in the nation currently funded by the National Cancer Institute Community Oncology Research Program (NCORP). NCORP is a national network of cancer care investigators, providers, academia, and other organizations that care for diverse populations in health systems and conduct high quality trials that are aimed to better understand oncology through studies that work to prevent and/ or care for cancer.
For additional resource information visit https://ncorp.cancer.gov/ or http://jco.ascopubs.org/
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma
